Latest Insider Transactions at Nuvectis Pharma, Inc. (NVCT)
This section provides a real-time view of insider transactions for Nuvectis Pharma, Inc. (NVCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nuvectis Pharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nuvectis Pharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
310
+0.01%
|
$6,200
$20.3 P/Share
|
|
May 17
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
142
+0.01%
|
$2,698
$19.55 P/Share
|
|
May 16
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
100
+0.01%
|
$1,900
$19.28 P/Share
|
|
May 16
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.03%
|
$19,000
$19.32 P/Share
|
|
May 13
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
700
+0.02%
|
$12,600
$18.1 P/Share
|
|
May 12
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
670
+0.03%
|
$10,050
$15.4 P/Share
|
|
May 12
2022
|
Matthew L. Kaplan Director |
BUY
Open market or private purchase
|
Direct |
3,000
+4.1%
|
$48,000
$16.72 P/Share
|
|
May 12
2022
|
Kenneth Hoberman Director |
BUY
Open market or private purchase
|
Direct |
6,000
+9.81%
|
$102,000
$17.4 P/Share
|
|
May 12
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
12,245
+0.14%
|
$195,920
$16.09 P/Share
|
|
May 12
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
1,278
+0.03%
|
$19,170
$15.68 P/Share
|
|
Apr 01
2022
|
Ron Bentsur Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+3.91%
|
-
|
|
Apr 01
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+4.62%
|
-
|
|
Apr 01
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+4.55%
|
-
|
|
Mar 28
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+0.14%
|
$28,000
$7.05 P/Share
|
|
Mar 17
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
7,000
+0.25%
|
$49,000
$7.63 P/Share
|
|
Feb 14
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
8,000
+0.28%
|
$40,000
$5.88 P/Share
|
|
Feb 10
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
8,500
+0.3%
|
$51,000
$6.34 P/Share
|
|
Feb 07
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.36%
|
$120,000
$6.09 P/Share
|
|
Feb 07
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
846
+0.07%
|
$2,538
$3.47 P/Share
|
|
Feb 07
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
800
+0.07%
|
$2,400
$3.88 P/Share
|
|
Feb 04
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
212,500
+3.6%
|
$850,000
$4.45 P/Share
|
|
Feb 04
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
2,100
+0.18%
|
$6,300
$3.38 P/Share
|
|
Feb 04
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
3,800
+0.32%
|
$11,400
$3.35 P/Share
|